Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 16 October 2009:
Vol. 326. no. 5951, pp. 370 - 371
DOI: 10.1126/science.1176116
Prev | Table of Contents | Next

Policy Forum

Intellectual Property:

Balancing Innovation and Access: Patent Challenges Tip the Scales

Matthew J. Higgins1,*,{dagger} and Stuart J. H. Graham1,2,*

Improvements in pharmaceutical research and development (R&D) depend on product innovation. But the number of new compounds approved annually by the U.S. Food and Drug Administration (FDA) has fallen from an average of 35 in 1996–2001 to 20 in 2002–07 (1). This decline stems from several factors (2); however, one particular U.S. regulation—the Paragraph IV patent challenge—is increasingly stifling new drug innovation and deserves our attention.

1 College of Management, Georgia Institute of Technology, Atlanta, GA 30308, USA.
2 Berkeley Center for Law and Technology, University of California, Berkeley Law School, Berkeley, CA 94720, USA.

* The authors contributed equally to this work.

{dagger} Author for correspondence. E-mail: matt.higgins{at}mgt.gatech.edu

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)